Moomoo AI 已提取核心信息
Redhill Biopharma Ltd., a foreign private issuer, has submitted a Form 6-K to the United States Securities and Exchange Commission (SEC) for January 2024. The report includes several exhibits such as Securities Purchase Agreement, Warrant forms, and legal opinions from Goldfarb Gross Seligman & Co. and Haynes and Boone, LLP. The Form 6-K filing, which is not an offer to sell or a solicitation of an offer to buy securities, has been incorporated by reference into the company's various Registration Statements on Form S-8 and Form F-3 filed with the SEC over the years. The document was signed by CEO Dror Ben-Asher, indicating compliance with the requirements of the Securities Exchange Act of 1934.
Redhill Biopharma Ltd., a foreign private issuer, has submitted a Form 6-K to the United States Securities and Exchange Commission (SEC) for January 2024. The report includes several exhibits such as Securities Purchase Agreement, Warrant forms, and legal opinions from Goldfarb Gross Seligman & Co. and Haynes and Boone, LLP. The Form 6-K filing, which is not an offer to sell or a solicitation of an offer to buy securities, has been incorporated by reference into the company's various Registration Statements on Form S-8 and Form F-3 filed with the SEC over the years. The document was signed by CEO Dror Ben-Asher, indicating compliance with the requirements of the Securities Exchange Act of 1934.
外国私人发行人红山生物制药有限公司已向美国证券交易委员会（SEC）提交了2024年1月的6-K表格。该报告包括一些证物，例如证券购买协议、认股权证表格以及来自Goldfarb Gross Seligman & Co. 和Haynes and Boone, LLP的法律意见书。6K表格申请不是出售要约或征集购买证券要约，已通过引用方式纳入公司多年来向美国证券交易委员会提交的关于S-8表格和F-3表格的各种注册声明。该文件由首席执行官德罗尔·本·阿舍尔签署，表明遵守了1934年《证券交易法》的要求。
外国私人发行人红山生物制药有限公司已向美国证券交易委员会（SEC）提交了2024年1月的6-K表格。该报告包括一些证物，例如证券购买协议、认股权证表格以及来自Goldfarb Gross Seligman & Co. 和Haynes and Boone, LLP的法律意见书。6K表格申请不是出售要约或征集购买证券要约，已通过引用方式纳入公司多年来向美国证券交易委员会提交的关于S-8表格和F-3表格的各种注册声明。该文件由首席执行官德罗尔·本·阿舍尔签署，表明遵守了1934年《证券交易法》的要求。
有用
没用